Refine
Year of publication
- 2024 (4)
- 2023 (11)
- 2022 (17)
- 2021 (9)
- 2020 (12)
- 2019 (16)
- 2018 (22)
- 2017 (12)
- 2016 (44)
- 2015 (30)
- 2014 (43)
- 2013 (29)
- 2012 (39)
- 2011 (28)
- 2010 (34)
- 2009 (30)
- 2008 (16)
- 2007 (20)
- 2006 (17)
- 2005 (20)
- 2004 (15)
- 2003 (14)
- 2002 (18)
- 2001 (18)
- 2000 (12)
- 1999 (16)
- 1998 (31)
- 1997 (25)
- 1996 (19)
- 1995 (36)
- 1994 (29)
- 1993 (21)
- 1992 (27)
- 1991 (15)
- 1990 (20)
- 1989 (20)
- 1988 (19)
- 1987 (16)
- 1986 (11)
- 1985 (7)
- 1984 (10)
- 1983 (10)
- 1982 (3)
- 1981 (3)
- 1980 (3)
- 1979 (8)
- 1978 (2)
- 1976 (2)
- 1975 (3)
- 1973 (2)
- 1972 (2)
- 1971 (2)
Institute
- Fachbereich Chemie und Biotechnologie (892) (remove)
Has Fulltext
- no (892) (remove)
Language
- English (537)
- German (352)
- Multiple languages (2)
- Spanish (1)
Document Type
- Article (588)
- Patent (117)
- Book (65)
- Conference: Meeting Abstract (55)
- Conference Proceeding (34)
- Part of a Book (21)
- Report (5)
- Doctoral Thesis (3)
- Conference Poster (1)
- Preprint (1)
Keywords
- Heparin (3)
- Chemometrics (2)
- IR spectroscopy (2)
- NMR spectroscopy (2)
- Principal component analysis (2)
- Standardization (2)
- (R)- or (S)- gamma-valerolactone (1)
- 4-hydroxy valeric acid (1)
- ABE (1)
- Acid crash (1)
NVS123 is a poorly water-soluble protease 56 inhibitor in clinical development. Data from in vitro hepatocyte studies suggested that NVS123 is mainly metabolized by CYP3A4. As a consequence of limited solubility, NVS123 therapeutic plasma exposures could not be achieved even with high doses and optimized formulations. One approach to overcome NVS123 developability issues was to increase plasma exposure by coadministrating it with an inhibitor of CYP3A4 such as ritonavir. A clinical boost effect was predicted by using physiologically based pharmacokinetic (PBPK) modeling. However, initial boost predictions lacked sufficient confidence because a key parameter, fraction of drug metabolized by CYP3A4 (ƒₘCYP3A4), could not be estimated with accuracy on account of disconnects between in vitro and in vivo preclinical data. To accurately estimate ƒₘCYP3A4 in human, an in vivo boost effect study was conducted using CYP3A4-humanized mouse model which showed a 33- to 56-fold exposure boost effect. Using a top-down approach, human ƒₘCYP3A4 for NVS123 was estimated to be very high and included in the human PBPK modeling to support subsequent clinical study design. The combined use of the in vivo boost study in CYP3A4-humanized mouse model mice along with PBPK modeling accurately predicted the clinical outcome and identified a significant NVS123 exposure boost (∼42-fold increase) with ritonavir.
Bacterial cellulose (BC) is a biopolymer produced by different microorganisms, but in biotechnological practice, Komagataeibacter xylinus is used. The micro- and nanofibrillar structure of BC, which forms many different-sized pores, creates prerequisites for the introduction of other polymers into it, including those synthesized by other microorganisms. The study aims to develop a cocultivation system of BC and prebiotic producers to obtain BC-based composite material with prebiotic activity. In this study, pullulan (PUL) was found to stimulate the growth of the probiotic strain Lactobacillus rhamnosus GG better than the other microbial polysaccharides gellan and xanthan. BC/PUL biocomposite with prebiotic properties was obtained by cocultivation of Komagataeibacter xylinus and Aureobasidium pullulans, BC and PUL producers respectively, on molasses medium. The inclusion of PUL in BC is proved gravimetrically by scanning electron microscopy and by Fourier transformed infrared spectroscopy. Cocultivation demonstrated a composite effect on the aggregation and binding of BC fibers, which led to a significant improvement in mechanical properties. The developed approach for “grafting” of prebiotic activity on BC allows preparation of environmentally friendly composites of better quality.